TD Cowen analyst Tara Bancroft has maintained their bullish stance on CELC stock, giving a Buy rating on May 12.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Tara Bancroft has given her Buy rating due to a combination of factors related to Celcuity’s ongoing clinical trials and potential market opportunities. The Phase III VIKTORIA-1 trial for gedatolisib, targeting HR+/HER2- breast cancer patients, is a significant focus. The trial’s data, expected in the third quarter, is anticipated to show meaningful progression-free survival (mPFS) improvements, which could enhance the drug’s market potential.
Bancroft also considers the trial’s design and patient population, which includes healthier patients compared to previous studies, as a positive factor. The potential for gedatolisib to achieve a 3+ month mPFS benefit over existing treatments is seen as a key driver of value. Additionally, insights from key opinion leaders and feedback from investors, physicians, and payors suggest that the anticipated mPFS improvements could meet or exceed market expectations, supporting the Buy rating.